|
German glass maker Schott has announced that it has added syringe and cartridge glass tubing capabilities to its existing state-of-the-art manufacturing capabilities in Jambusar, Gujarat to address the requirements of pharmaceutical packaging.
This has resulted in positioning the company as Asia's largest producer of syringe and cartridge glass tubing, it claims.
It is set to meet the surging demand for biologics like semaglutide (belonging to the GLP-1 receptor agonist class) used for weight management and control of blood sugar levels in patients with type 2 diabetes.
The GLP-1 segment alone is projected to witness a staggering CAGR of 33%. Also administered in a pre-filled syringe or cartridge, this launch positions the company in India to fully cater to all glass primary packaging needs of pharma, from glass tubing for vials and ampoules to the newly added syringes and cartridges, it added.
Sundeep Prabhu, sr. vice president sales & marketing, Schott Glass India, said, “As the first in India to locally manufacture high-precision syringe and cartridge glass tubing, we are not only elevating our operational capabilities but also reinforcing India's healthcare self-sufficiency. This investment aligns strongly with the ‘Make in India’ initiative and showcases our ongoing commitment to driving excellence, and economic growth in the country.”
Pawan Kumar Shukla, president & managing director of Schott Glass India, said, "By bringing local production of our high-precision syringe and cartridge FIOLAX glass tubing to India, we’re ensuring a stable and consistent supply chain for critical drug delivery systems. With highly accurate inner diameter control and our perfeXion quality system analysing 100,000 data points every minute, we aim to achieve zero-defect manufacturing.”
Schott Glass India, a wholly owned subsidiary of Schott AG, is active since 1998, and operates the company’s second-largest pharmaceutical tubing production site globally in Jambusar.
|